IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

news

Dec 12

Written By Lara Wilson

Lara Wilson

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML